Scarica l'app Stockscreener
24.76
0.36%
0.09
Dopo l'orario di chiusura:
24.78
0.02
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study - MSN
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter - The Motley Fool
Pfizer Hit With More Suits Over Depo-Provera - Law360
Pfizer (PFE) Valuation in Focus as Strong Clinical Results and New Approvals Spark Renewed Investor Optimism - simplywall.st
Why Pfizer’s Headwinds May Already Be In The Price (NYSE:PFE) - Seeking Alpha
IBM Ranks High For Flexible Roles And Training In AI And Cloud Computing - cnynews.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore - Yahoo
HER-2 Negative Breast Cancer Market 2025 Is Booming Worldwide - openPR.com
Heparin Calcium Market Set to Witness Massive Growth by 2032 - openPR.com
What Do Advances in Pfizer’s Vaccine Pipeline Mean for Its 2025 Valuation? - Yahoo Finance
Fact Check Team: Pfizer sued over alleged tumor risk from contraceptive injection - The National Desk
Pfizer's Cancer Data Did Little To Stoke The Stock. Is It A Buy Or A Sell? - Investor's Business Daily
December 5th Options Now Available For Pfizer (PFE) - Nasdaq
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 Million - The Globe and Mail
ABRYSVO Receives Expanded Public Funding Across Canadian Provinces for 2025-2026 RSV Season - Financial Times
Pfizer Stock (PFE) Shows Golden Cross After YTD Decline: Momentum Shift Imminent? - AskTraders.com
Nifedipine Medication Market is Going to Booming Growth 2025-2032 | Pfizer Inc., Novartis AG, Merck & Co., Inc. - openPR.com
Cancer Drugs Market Is Booming So Rapidly | Pfizer Inc., Novartis AG, Merck & Co., Inc. - openPR.com
Pfizer Inc. - Britannica
PFIZER INC : Buy rating from Jefferies - MarketScreener
You’ve Still Got It: Aging with Agency to Stay on Top of Your Health Year-Round - Pfizer
Bernstein Remains a Hold on Pfizer (PFE) - The Globe and Mail
Cambridge biotech launches with Pfizer deal, and other life sciences news - The Business Journals
Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ - BioSpace
Pfizer's Accord For A Healthier World Program Challenges Stability Study Norms - Bioprocess Online
Does the Recent 3% Gain Signal a Turning Point for Pfizer Shares? - simplywall.st
mRNA Therapeutics and Global Markets to 2030, Profiles of Leading CompaniesModerna, Pfizer, BioNTech, Merck, and SanofiResearchAndMarkets.com - The AI Journal
Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ (2025-10-21) - Seeking Alpha
2 Mega-Dividend Stocks With Yields As High As 7% - The Globe and Mail
Pfizer (PFE) Receives a Hold from Wells Fargo - The Globe and Mail
Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Relay Therapeutics (RLAY) - The Globe and Mail
Pfizer (PFE): Exploring Valuation as Shares Tick Higher Despite Sector Headwinds - Yahoo Finance
Pfizer's Phase 3 Success and GSK's Rollout Expansion Spark Momentum in the Global Malaria Vaccine Market - openPR.com
Lobbying Update: $2,730,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
What analyst consensus implies for Pfizer Inc. (PFE) stockWeekly Profit Report & Capital Efficient Trade Techniques - nchmf.gov.vn
RSI Check: Will Pfizer Inc. (Common Stock) (PFEB) stock deliver stable dividends2025 Analyst Calls & Accurate Entry and Exit Point Alerts - nchmf.gov.vn
How Pfizer Inc. stock performs in volatility spikesJuly 2025 Retail & Technical Pattern Based Buy Signals - nchmf.gov.vn
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect - sharewise.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Canc - GuruFocus
Pfizer, Inc. (PFE): Investor Outlook Reveals 17.54% Potential Upside Amid Strong Dividend Yield - DirectorsTalk Interviews
PFIZER INC : JP Morgan sticks Neutral - MarketScreener
Rally Mode: What analyst consensus implies for Pfizer Inc. (PFE) stockJuly 2025 PreEarnings & Technical Pattern Based Signals - nchmf.gov.vn
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
2 High-Yield Dividend Stocks Too Cheap to Ignore - Yahoo Finance
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer
Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener
Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Business Wire
Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire
Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS
What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn
How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer
Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener
0.17%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):